Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 5/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.44 |
| ▸ | PPM1B | O75688 | 2/20 | 0.41 |
| ▸ | PPP5C | P53041 | 2/20 | 0.39 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21360341 | 1.00 | TFPI2 (0.45) | TFPI2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL9880141 | 0.83 | TFPI2 (0.56) | TFPI2PPM1BPPP5CPPP2CANPY4R | |
| SCHEMBL20459524 | 0.83 | TFPI2 (0.46) | TFPI2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL13001974 | 0.83 | CHRNB2 (0.43) | TFPI2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL14135612 | 0.82 | TFPI2 (0.46) | TFPI2PPM1BPPP5CPPP2CANPY4R | |
| SCHEMBL19177682 | 0.82 | TSHR (0.40) | TFPI2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL9880146 | 0.81 | TFPI2 (0.60) | TFPI2PPM1BPPP5CPPP2CANPY4R | |
| SCHEMBL16451149 | 0.78 | PPM1B (0.45) | TFPI2PPM1BPPP5CPPP2CANPY4R | |
| SCHEMBL9880153 | 0.77 | HSD11B1 (0.45) | TFPI2PPM1BPPP5CPPP2CANPY4R | |
| SCHEMBL9880150 | 0.75 | TFPI2 (0.73) | TFPI2CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-3258930-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200179375-A1 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES | LIXTE BIOTECHNOLOGY, INC. | 2020-06-11 | — | — | US | disclosed |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | LIXTE BIOTECHNOLOGY, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019113155-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | LIXTE BIOTECHNOLOGY, INC. | 2019-06-06 | — | — | US | disclosed |
| EP-2870161-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | LIXTE BIOTECHNOLOGY INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2010147612-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | TFPI2 4324/4885CHRNB2 54/4885CHRNA3 38/4885 |
| US-20200179375-A1 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES | PPP2CA, PPP2R2A, PPM1A | TFPI2 4454/4885CHRNB2 1224/4885CHRNA3 1568/4885 |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | PPP2CA, PPP3CA, PPP6C | TFPI2 3732/4885CHRNB2 2596/4885CHRNA3 3408/4885 |
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | MCL1, MYD88, SAMHD1 | TFPI2 4378/4885CHRNB2 4748/4885CHRNA3 4672/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TFPI2 4843/4885CHRNB2 4107/4885CHRNA3 3912/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885CHRNB2 4338/4885CHRNA3 4160/4885 |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | PPP2CA, PPP2R2A, PPM1A | TFPI2 1195/4885CHRNB2 3929/4885CHRNA3 4300/4885 |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | PPP2CA, PPP3CA, PPP6C | TFPI2 3732/4885CHRNB2 2596/4885CHRNA3 3408/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885CHRNB2 4338/4885CHRNA3 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.